A Solitary Fibrous Tumour of the Eyelid

Irene Pecorella\textsuperscript{a} Filippo Cruciani\textsuperscript{b} Valeria Russo\textsuperscript{b}

\textsuperscript{a}Department of Radiologic, Oncologic and Anatomic Pathology, \textsuperscript{b}Department of Sense Organs, University of Rome ‘Sapienza’, Rome, Italy

\textbf{Key Words}
Solitary fibrous tumour · Eyelid · CD34 · Progesterone receptor · Bcl-2

\textbf{Abstract}
\textbf{Objective:} To report a case of palpebral solitary fibrous tumour (SFT).
\textbf{Clinical Presentation and Intervention:} An elderly man presented with a slow-growing painless mass in the lower conjunctival fornix in the left eye. The lesion was excised and it measured 0.9 cm in maximum diameter. The microscopic features were characteristic of a benign SFT, with immunohistochemical reactivity for vimentin, CD34 and Bcl-2 protein. Nuclear staining for progesterone receptor was also observed. \textbf{Conclusion:} This tumour displayed a benign course, with no recurrence after excision. CD34 immunohistochemistry proved to be a useful adjunct to the microscopic diagnosis.

\textbf{Introduction}

Solitary fibrous tumour (SFT), a benign mesenchymal fibroblast-like tumour, was first described as a primary mesothelial spindle-cell tumour of the pleura in 1931 [1]. With the advent of immunohistochemistry a fibroblastic origin, occasionally with myofibroblastic differentiation, was firmly established. It was also established that SFTs are ubiquitous neoplasms with both pleural and extrapleural distribution, the most common extrapleural sites being the orbits and the extremities. Other sites that have been reported include pericardium, lung, mediastinum, peritoneum and retroperitoneum, upper respiratory tract (nasal cavity, sinuses and nasopharynx), meninges, thyroid, parotid, adrenal gland, breast, genito-urinary tract (kidney, vulva, urinary bladder and the prostate) and liver. Herein we report a case of SFT of the eyelid, a site of origin that has rarely been described.

\textbf{Case Report}

A 78-year-old man presented with a slow-growing painless hard-elastic, palpable mass in the lower conjunctival fornix in the left eye, which was first noticed 1 year earlier. The size of the lesion was 0.9 cm in maximum diameter. The lesion was excised and it measured 0.9 cm in maximum diameter. The microscopic features were characteristic of a benign SFT, with immunohistochemical reactivity for vimentin, CD34 and Bcl-2 protein. Nuclear staining for progesterone receptor was also observed. \textbf{Conclusion:} This tumour displayed a benign course, with no recurrence after excision. CD34 immunohistochemistry proved to be a useful adjunct to the microscopic diagnosis.

\textcopyright{} 2013 S. Karger AG, Basel
cells, mitotic activity, pleomorphism, or atypia were identified. There was strong and uniform immunohistochemical reactivity for vimentin, CD34 and B-cell lymphoma 2 (Bcl-2) protein on paraffin-embedded tissue sections (fig. 2a, b). Nuclear staining for progesterone receptor (PR) was also observed (fig. 2c). Staining for S-100 protein, CD99, KIT/CD117 and actin smooth muscle was negative. The number of proliferating Ki-67-positive nuclei was low, with values averaging 1%.

Discussion

The tumoural mass in the eyelid of this patient was microscopically consistent with an SFT. However, in consideration of the unusual location, CD34 immunotyping of the neoplastic cells was performed to confirm the diagnosis. Indeed, a widely distributed family of CD34+ interstitial spindle cells (so-called ‘dendritic interstitial cells’) are likely to be the cell of origin of SFT.

CD34, a myeloid progenitor cell antigen that is present in normal and neoplastic endothelial cells and in some other mesenchymal cells, including subsets of fibroblasts, is consistently positive in SFT. In addition to CD34, this case was also immunoreactive for vimentin and Bcl-2, as noted previously in similar tumours [2].

Before the widespread use of immunohistochemical studies and CD34 labelling, the diagnosis of orbital and periorbital SFT based solely on the histopathological findings was confused with other benign lesions, such as fibrous histiocytoma and HPC. SFT as an entity is rarely diagnosed clinically.
Recently, it has been described that steroid hormone receptors, PR in particular, may be expressed by extra-pleural SFT. It has been proposed that progesterone may participate as a growth factor in many CD34+ neoplasms. According to the study of Bongiovanni et al. [2], PR+ is a feature of SFT showing a higher proliferative activity and a trend toward recurrence. We also found the present tumour to be PR+; however, the patient failed to show evidence of disease after 24 months of follow-up. Bcl-2 protein displays a restricted pattern of expression in adult mammalian tissues, being confined to stem cells, to long-lived cells, and to hormone-responsive tissues. The expression of Bcl-2 in this case could be related to the presence of PR in the neoplastic tissue.

SFT occurs most commonly in adults and shows a slight male predominance as in this case. It is microscopically composed of uniform spindle cells arranged in interlacing fascicles. It exhibits alternating hypercellular areas and hypocellular areas with abundant thick, often keloid-like, hyalinized collagen. Furusato et al. [3] recently reviewed 41 fibroblastic orbital tumours, retrieved from the consultation file of the Armed Forces Institute of Pathology, originally diagnosed as HPC, fibrous histiocytomas and giant cell angiofibromas. However, all the lesions showed overlapping morphological and immunohistochemical features, including CD34 positivity, varying in cellularity, stromal collagen, and the presence of giant cells. Similarities with giant cell fibroblastoma were also evident. The majority of tumours within the HPC-SFT spectrum are defined as ‘indeterminate’, as their histologic or antigenic profiles are not classic for HPC or SFT. Despite considerable morphologic overlap of SFT with HPC, the differential diagnosis can be made using CD34 staining, which is more often patchy and weak in HPC. Furthermore, HPC shows more diffuse vascularity with more prominent staghorn vessels and rounded tumour cells. Of note, according to the World Health Organization, most of the tumours formerly diagnosed as HPC are considered to be extrapleural cellular variants of SFTs. Lipomatous HPC is another entity presently considered to represent, in most cases, a fat-containing variant of SFT.

CD34 is an efficient tool for differential diagnosis, being present in 79–100% of SFT cases [4]. Unfortunately, it is not entirely specific for SFT or lesions in the HPC-SFT spectrum and expresses in a variety of spindle cell neoplasms, such as HPC, dermatofibrosarcoma protuberans, Kaposi’s sarcoma, spindle cell lipoma, gastrointestinal stromal tumours, or nerve sheath tumours. Furthermore, malignant transformation of SFT may be associated with conversion of a CD34+ lesion to a CD34– lesion [5].

Eyelid SFT appears to be very infrequent. So far only 6 other cases in the HPC-SFT spectrum have been described in the literature (table 1). Of them, just 1 case was diagnosed as SFT. Previous reports of eyelid lesions from SFT appear to be eyelid extensions or coexisting eyelid

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Site</th>
<th>Size, cm</th>
<th>Patient’s age</th>
<th>Patient’s sex</th>
<th>Complaints</th>
<th>Outcome</th>
<th>Histology/immunohistochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>RL</td>
<td>3</td>
<td>35</td>
<td>M</td>
<td>enlarging painless mass for 12 months</td>
<td>FP for 6 months</td>
<td>HPC-SFT (indeterminate)/CD34+</td>
</tr>
<tr>
<td>7</td>
<td>Lu</td>
<td>2</td>
<td>78</td>
<td>F</td>
<td>painless mass for 8 years</td>
<td>not removed</td>
<td>GCA/CD34+–</td>
</tr>
<tr>
<td>8</td>
<td>RL</td>
<td>2</td>
<td>40</td>
<td>M</td>
<td>periocular painless mass for 6 months</td>
<td>FP for at least 24 months</td>
<td>SFT/CD34+</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>30</td>
<td>M</td>
<td>oedematous, pedunculated, painless masses already resected twice</td>
<td>FP for 8 months</td>
<td>GCA/CD34+, Bcl-2+</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Ll</td>
<td>1</td>
<td>31</td>
<td>F</td>
<td>enlarging mass for 3 months</td>
<td>FP at 8 months</td>
<td>HPC/CD34–</td>
</tr>
<tr>
<td>11</td>
<td>RL</td>
<td>1.4</td>
<td>24</td>
<td>M</td>
<td>painless conjunctival mass for 12 months</td>
<td>GCA/CD34+, Bcl-2+</td>
<td></td>
</tr>
<tr>
<td>Present case</td>
<td>Ll</td>
<td>0.9</td>
<td>78</td>
<td>M</td>
<td>periocular mass</td>
<td>FP for 24 months</td>
<td>SFT/CD34+, Bcl-2+, PR+</td>
</tr>
</tbody>
</table>

R = Right eyelid; L = left eyelid; l = lower eyelid; u = upper eyelid; GCA = giant cell angiofibroma; FP = follow-up period.

### Table 1. Eyelid lesions of the HPC-SFT spectrum described in the literature
symptoms affected by a primary orbital lesion [6]. Because of the paucity of reported primary SFT of the eyelid, information concerning etiologic factors, treatment and prognosis is limited and new additions to the literature may prove useful.

**Conclusion**

This tumour displayed a benign course, with no recurrence after excision. CD34 immunohistochemistry proved to be a useful adjunct to the microscopic diagnosis.

**References**